Last reviewed · How we verify
Xueshuantong lyophilized powder
Xueshuantong is a traditional Chinese medicine-derived lyophilized powder that promotes blood circulation and removes blood stasis to improve microvascular perfusion.
Xueshuantong is a traditional Chinese medicine-derived lyophilized powder that promotes blood circulation and removes blood stasis to improve microvascular perfusion. Used for Acute ischemic stroke, Cerebral infarction, Angina pectoris.
At a glance
| Generic name | Xueshuantong lyophilized powder |
|---|---|
| Also known as | Zhusheyong Xueshuantong (donggan), WS-10460(ZD-0460)-2002-2011Z |
| Sponsor | Dongzhimen Hospital, Beijing |
| Drug class | Traditional Chinese medicine extract |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Neurology |
| Phase | FDA-approved |
Mechanism of action
The drug is derived from Panax notoginseng (Burbank ginseng) and works through multiple pathways including antiplatelet aggregation, anticoagulation, and vasodilation. It is believed to enhance blood flow, reduce blood viscosity, and improve tissue oxygenation by removing pathological blood stasis, a key concept in traditional Chinese medicine.
Approved indications
- Acute ischemic stroke
- Cerebral infarction
- Angina pectoris
- Peripheral vascular disease
Common side effects
- Bleeding or hemorrhage
- Allergic reaction
- Gastrointestinal upset
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xueshuantong lyophilized powder CI brief — competitive landscape report
- Xueshuantong lyophilized powder updates RSS · CI watch RSS
- Dongzhimen Hospital, Beijing portfolio CI